Our findings demonstrated that doxorubicin treatment increased SH3GL1 expression in DLBCL cells, indicating that SH3GL1 might involve in the modulation of doxorubicin‐induced cell death. Here, SH3GL1 is linked to diffuse large B-cell lymphoma.